Mona Shahriari, MD, and Valerie D. Callender, MD, discuss trial diversity, better outcome measures, and how investigators can earn patient trust.
News|Articles|December 11, 2023
Rheumatoid Arthritis Quiz: Anxiety and Depression in RA
Author(s)Ingrid Torjesen
It is common for patients with rheumatoid arthritis to have mental health conditions. Test your knowledge of the impact of anxiety and depression in rheumatoid arthritis with this quiz.
Advertisement
What proportion of rheumatoid arthritis outpatients screen positive for anxiety?
Advertisement
Related to this article
Compass Pathways completed its NDA for COMP360 based on 2 phase 3 trials and a phase 2b study in > 1000 participants with highly chronic TRD.
In a UCB-funded network meta-analysis of 17 trials, bimekizumab ranked first on HiSCR50, HiSCR75, and IHS4-55 among HS drugs at Weeks 12 - 16.
The 2027 GOLD report recommends a LAMA for group A, defines 6 pre-COPD types, and expands CT, rehabilitation, and cardiovascular guidance for COPD.
Topline results presented at The Liver Meeting showed 79% of patients with HDV reached undetectable HDV RNA at 48 weeks with monthly elebsiran plus tobevibart.
Kausik Ray, MD, MBChB, MPhil, discusses Lp(a)HORIZON, remnant cholesterol targets, enlicitide, and the lipid outcome trials to watch in 2027.
In the phase 2b IMPACT trial, up to 42.9% of patients with MASH achieved concurrent liver fat, ALT, and stiffness responses on pemvidutide vs 3.3% on placebo.
In 757 adults with severe hypertriglyceridemia, plozasiran cut acute pancreatitis events by 78% overall and 91% in those with recent prior pancreatitis.
Advertisement
Advertisement
Trending on HCPLive
1
ESSENCE: Semaglutide Improves Liver Markers in MASH Without Obesity
2
Lp(a)HORIZON, Oral PCSK9s, and 2027 Lipid Trials, with Kausik Ray, MD, MBChB, MPhil
3
Single Dose of CIDEB siRNA Normalizes Liver Fat in MASLD Through 36 Weeks
4
Elebsiran Plus Tobevibart Suppresses HDV RNA in Phase 3 ECLIPSE 1 Trial
5